EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 75,683 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $40.81, for a total value of $3,088,623.23. Following the completion of the transaction, the insider now owns 308,377 shares in the company, valued at $12,584,865.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Graham Peter Lidgard also recently made the following trade(s):

  • On Friday, September 1st, Graham Peter Lidgard sold 45,775 shares of EXACT Sciences stock. The shares were sold at an average price of $41.49, for a total value of $1,899,204.75.

Shares of EXACT Sciences Co. (EXAS) traded up 1.51% during mid-day trading on Thursday, reaching $42.99. The company’s stock had a trading volume of 1,369,209 shares. The company’s market capitalization is $5.12 billion. The firm’s 50 day moving average price is $39.28 and its 200-day moving average price is $31.61. EXACT Sciences Co. has a 1-year low of $13.05 and a 1-year high of $43.29.

EXACT Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.10. The company had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. EXACT Sciences had a negative net margin of 53.41% and a negative return on equity of 29.05%. On average, analysts predict that EXACT Sciences Co. will post ($1.18) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/07/exact-sciences-co-exas-insider-graham-peter-lidgard-sells-75683-shares.html.

A number of research analysts recently commented on EXAS shares. Vetr cut EXACT Sciences from a “hold” rating to a “sell” rating and set a $34.70 price objective on the stock. in a report on Wednesday, July 12th. Leerink Swann set a $45.00 price objective on EXACT Sciences and gave the company a “buy” rating in a report on Thursday, August 24th. Canaccord Genuity upped their price objective on EXACT Sciences from $38.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Zacks Investment Research upgraded EXACT Sciences from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Tuesday, June 27th. Finally, Roth Capital upped their price objective on EXACT Sciences from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, July 26th. Six investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. EXACT Sciences has a consensus rating of “Buy” and an average price target of $40.98.

Several institutional investors and hedge funds have recently made changes to their positions in the business. Advisor Group Inc. boosted its holdings in shares of EXACT Sciences by 0.8% in the 2nd quarter. Advisor Group Inc. now owns 7,866 shares of the medical research company’s stock valued at $270,000 after purchasing an additional 65 shares during the last quarter. Suntrust Banks Inc. boosted its holdings in shares of EXACT Sciences by 1.5% in the 1st quarter. Suntrust Banks Inc. now owns 18,478 shares of the medical research company’s stock valued at $436,000 after purchasing an additional 277 shares during the last quarter. Stifel Financial Corp boosted its holdings in shares of EXACT Sciences by 1.5% in the 1st quarter. Stifel Financial Corp now owns 21,475 shares of the medical research company’s stock valued at $506,000 after purchasing an additional 310 shares during the last quarter. Prudential Financial Inc. boosted its holdings in shares of EXACT Sciences by 3.0% in the 1st quarter. Prudential Financial Inc. now owns 11,141 shares of the medical research company’s stock valued at $263,000 after purchasing an additional 320 shares during the last quarter. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of EXACT Sciences by 5.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 9,640 shares of the medical research company’s stock valued at $341,000 after purchasing an additional 511 shares during the last quarter. Institutional investors own 85.22% of the company’s stock.

EXACT Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences Co. and related companies with MarketBeat.com's FREE daily email newsletter.